Response to Tigilanol Tiglate in Dogs with Mast Cell Tumors
Tigilanol tiglate is gaining recognition as an effective local treatment for mast cell tumors (MCTs) in dogs. Despite its growing use, data on its response rate and long-term effectiveness have been limited. A recent multicenter, retrospective study aimed to address this gap by examining the treatment outcomes in 149 dogs with 151 MCTs.
Study Overview: Veterinary oncologists from the American College of Veterinary Internal Medicine (ACVIM) oncology listserv were surveyed, providing information on dogs treated with tigilanol tiglate. Data were collected at three key intervals: initial treatment, one month after treatment, and one year post-treatment.
Key Findings:
Response Rate: 75% of dogs achieved a complete response one month after a single dose of tigilanol tiglate.
Durability: Of the dogs with available one-year data, 64% maintained a complete response after one year.
Wound Formation: As expected, wound formation occurred within a median of 7 days post-treatment, with the median wound size being 4.71 cm². Wound healing took a median of 30 days, although this varied (range: 14-154 days).
Tumor and Wound Correlation: A moderate correlation was found between the size of the tumor and the wound area post-treatment.
Conclusion: Tigilanol tiglate presents a reliable local treatment option for canine mast cell tumors, showing high response rates and predictable wound healing timelines. However, client education and careful case selection are essential due to the unique mode of action and wound formation following treatment. This study provides valuable insights for veterinarians considering tigilanol tiglate for managing MCTs in dogs.
Read full article here: Response to tigilanol tiglate in dogs with mast cell tumors
